<DOC>
	<DOCNO>NCT00702650</DOCNO>
	<brief_summary>Testosterone replacement treatment effective way treat hypogonadism men . Acrux propriety testosterone replacement product- Testosterone MD-Lotion ( cutaneous solution ) , study evaluate efficacy via pharmacokinetics various dos product . The study also assess safety product .</brief_summary>
	<brief_title>A Titration Trial Determine Effectiveness Testosterone MD-Lotion ( Cutaneous Solution ) Formulations</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male subject prior document definitive diagnosis hypogonadism evidence previously document : Hypothalamic , pituitary testicular disorder age relate idiopathic hypogonadism Screening serum testosterone less equal 300 ng/dL ( base average two morning sample take least 30 minute apart ) Were currently receive treatment hypogonadism accordance approve labelling , Investigator 's opinion eligible receive treatment Body Mass Index ( BMI ) &lt; 35.0 kg/m^2 Haemoglobin level screen great equal 11.5 g/dL Adequate venous access leave right arm allow collection number sample venipuncture Ability communicate trial staff , understand Trial Information Sheet sign Written Informed Consent Forms ; willing follow Protocol requirement comply Protocol restriction procedure Current use long act testosterone injectables NebidoÂ® Any significant history allergy and/or sensitivity drug product excipients , include history sensitivity testosterone and/or sunscreens Any clinically significant chronic illness find screen physical exam and/or laboratory test make undesirable Investigator enrol trial subject trial and/or Investigator 's opinion , would interfere trial objective safety subject Chronic skin disorder ( e.g . eczema , psoriasis ) likely interfere transdermal drug absorption Men suspect reversible hypogonadism Any man testosterone therapy contraindicate , include : Known suspected carcinoma ( history carcinoma ) prostate clinically significant symptom benign prostatic hyperplasia and/or clinically significant symptom low urinary obstruction International Prostate Symptom Scores ( IPSS ) score great equal 19 Known suspect carcinoma ( history carcinoma ) breast Severe liver disease ( i.e . cirrhosis , hepatitis liver tumours liver function test &gt; 2 time upper limit normal range value ) Active deep vein thrombosis , thromboembolic disorder document history condition Current significant cerebrovascular coronary artery disease Untreated sleep apnoea Haematocrit &gt; 51 Untreated moderate severe depression Men clinically significant prostate exam ( irregularity nodules palpate ) clinically significant elevate serum Prostate Specific Antigen ( PSA ) level ( &gt; 4 ng/mL ) , age adjust reference range PSA value Current history drug alcohol abuse ( 4 standard drink per day and/or abnormal liver function test &gt; 2 time upper limit normal range value ) Men take concomitant medication ( prescribe , overthecounter complementary ) would affect sex hormone bind globulin ( SHBG ) testosterone concentration metabolism , warfarin , insulin , opiates , Gonadotropinreleasing hormone ( GnRH ) , 5 alpha reductase inhibitor , propanolol , oxyphenbutazone , corticosteroid ( except physiological replacement dos ) , estradiol Men involve sport screen anabolic steroid Men uncontrolled diabetes ( haemoglobin A1c [ HbA1c ] great equal 10 % ) Men currently take investigational product , receive investigational product within 28 day prior screen 5 halflives Any contraindication blood sample Subjects intend surgical procedure course trial Subjects partner child bear potential willing use adequate contraception duration trial Subjects whose partner pregnant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>